CL2011003003A1 - Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. - Google Patents

Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.

Info

Publication number
CL2011003003A1
CL2011003003A1 CL2011003003A CL2011003003A CL2011003003A1 CL 2011003003 A1 CL2011003003 A1 CL 2011003003A1 CL 2011003003 A CL2011003003 A CL 2011003003A CL 2011003003 A CL2011003003 A CL 2011003003A CL 2011003003 A1 CL2011003003 A1 CL 2011003003A1
Authority
CL
Chile
Prior art keywords
phospholipid
analog polypeptide
native
surfactant protein
useful
Prior art date
Application number
CL2011003003A
Other languages
English (en)
Inventor
Fausto Pivetti
Monica Bocchi
Raschini Annamaria Soliani
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011003003(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2011003003A1 publication Critical patent/CL2011003003A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0082Lung surfactant, artificial mucus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

Composición tensioactiva reconstituida que comprende un polipéptido análogo a la proteína tensioactiva sp-c nativa; agente tensioactivo; formulación farmacéutica; kit.
CL2011003003A 2009-06-05 2011-11-25 Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. CL2011003003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09162052 2009-06-05

Publications (1)

Publication Number Publication Date
CL2011003003A1 true CL2011003003A1 (es) 2012-05-18

Family

ID=41055357

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003003A CL2011003003A1 (es) 2009-06-05 2011-11-25 Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.

Country Status (35)

Country Link
US (1) US8399406B2 (es)
EP (1) EP2438086B1 (es)
JP (1) JP5666569B2 (es)
KR (1) KR101668137B1 (es)
CN (1) CN102459327B (es)
AR (1) AR076973A1 (es)
AU (1) AU2010256066B2 (es)
BR (1) BRPI1010120B1 (es)
CA (1) CA2764454C (es)
CL (1) CL2011003003A1 (es)
CO (1) CO6470858A2 (es)
CY (1) CY1118676T1 (es)
DK (1) DK2438086T3 (es)
EA (1) EA021163B1 (es)
ES (1) ES2621974T3 (es)
GE (1) GEP20135967B (es)
HR (1) HRP20170445T1 (es)
HU (1) HUE034053T2 (es)
IL (1) IL216718A (es)
JO (1) JO3226B1 (es)
LT (1) LT2438086T (es)
MA (1) MA33374B1 (es)
ME (1) ME01279B (es)
MX (1) MX2011012951A (es)
MY (1) MY159464A (es)
NZ (1) NZ596848A (es)
PE (1) PE20120541A1 (es)
PL (1) PL2438086T3 (es)
PT (1) PT2438086T (es)
SG (1) SG176305A1 (es)
SI (1) SI2438086T1 (es)
TN (1) TN2011000558A1 (es)
TW (1) TWI457132B (es)
UA (1) UA103526C2 (es)
WO (1) WO2010139442A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2012122544A2 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
WO2013120058A2 (en) * 2012-02-09 2013-08-15 University Of Rochester Novel sp-b & sp-c peptides, synthetic lung surfactants, and use thereof
US9074018B2 (en) 2012-11-21 2015-07-07 Chiesi Farmaceutici S.P.A. Reconstituted pulmonary surfactants
CN104382942A (zh) * 2014-11-05 2015-03-04 烟台东诚药业集团股份有限公司 一种猪肺表面活性物质混悬液制备新工艺
EP3106090A1 (en) 2015-06-15 2016-12-21 CHIESI FARMACEUTICI S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
HK1247140A1 (zh) 2015-04-22 2018-09-21 奇斯药制品公司 用於药物有效地呼吸同步递送到肺部的方法和系统
US11311691B2 (en) 2015-04-28 2022-04-26 Chiesi Farmaceutici S.P.A Device for facilitating the administration of a medicament to the lung by a catheter
CA3016810C (en) * 2016-03-07 2024-04-02 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for administering ppar.gamma. agonists, surfactant peptides and phospholipids
CN109496159A (zh) 2016-07-28 2019-03-19 奇斯药制品公司 用于递送雾化药剂的方法和系统
BR112019003673A2 (pt) 2016-08-24 2019-05-21 Chiesi Farmaceutici S.P.A. formulação farmacêutica, uso de uma formulação farmacêutica e método para evitar o aumento da viscosidade durante o armazenamento de uma formulação farmacêutica
ES2892903T3 (es) 2016-10-26 2022-02-07 Chiesi Farm Spa Dispositivo para facilitar la administración de un medicamento a los pulmones por medio de un catéter
BR112019012922A2 (pt) 2016-12-22 2019-12-10 Chiesi Farm Spa combinação de um surfactante pulmonar, uso de uma combinação de um surfactante pulmonar e kit
TW201927286A (zh) 2017-12-15 2019-07-16 義大利商凱西製藥公司 用於噴霧投藥之包含肺表面張力素的藥學調配物
WO2019115771A1 (en) 2017-12-15 2019-06-20 Pari Pharma Gmbh Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method
JP7378425B2 (ja) 2018-04-23 2023-11-13 シエシー ファルマセウティチィ ソシエタ ペル アチオニ 肺サーファクタントおよびbpdの予防のためのステロイドを含む治療的組合せ
EP3666315A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3666316A1 (en) 2018-12-14 2020-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
EP3843105A1 (en) 2019-12-23 2021-06-30 PARI Pharma GmbH Control device for aerosol nebulizer system
US12606609B2 (en) 2020-01-28 2026-04-21 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties
EP4366691A1 (en) 2021-07-05 2024-05-15 Chiesi Farmaceutici S.p.A. Process for the preparation of a pulmonary surfactant
EP4411745A1 (en) 2023-02-01 2024-08-07 Pari Medical Holding GmbH Medical evaluation method, aerosol nebulizer and medical evaluation system
EP4464354A1 (en) 2023-05-15 2024-11-20 Pari Medical Holding GmbH Method of operating an inhalation device, inhalation device and inhalation device system for providing inhalation process/breath guiding
EP4464236A1 (en) 2023-05-15 2024-11-20 Pari Medical Holding GmbH Method of operating an inhalation device, inhalation device and inhalation device system for providing inhalation process feedback
WO2025024609A1 (en) * 2023-07-25 2025-01-30 Biosuperior Technology, Inc. Polypeptides for lung surfactant compositions
WO2025245275A1 (en) * 2024-05-21 2025-11-27 Molecular Express, Inc. Surfactant preparations for pulmonary delivery, and methods for the preparation and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501481A (ja) 1999-06-11 2003-01-14 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング サーファクタントタンパク質b(sp−b)改変体およびサーファクタントタンパク質c(sp−c)改変体を含有する医薬品製剤
ITMI20021058A1 (it) * 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
EP1481665A1 (en) * 2003-05-30 2004-12-01 CHIESI FARMACEUTICI S.p.A. Novel lipid mixtures for synthetic surfactants
JP4734328B2 (ja) * 2005-05-11 2011-07-27 ヤマサ醤油株式会社 肺サーファクタント蛋白質の安定化法
WO2008011559A2 (en) 2006-07-20 2008-01-24 University Of Rochester Synthetic lung surfactant and use thereof
PT2078038E (pt) * 2006-10-13 2013-12-12 Chiesi Farma Spa Agentes tensioativos reconstituídos apresentando propriedades melhoradas
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties

Also Published As

Publication number Publication date
AR076973A1 (es) 2011-07-20
CY1118676T1 (el) 2017-07-12
MX2011012951A (es) 2011-12-16
SG176305A1 (en) 2012-01-30
WO2010139442A1 (en) 2010-12-09
JO3226B1 (ar) 2018-03-08
HK1166332A1 (en) 2012-10-26
JP2012528810A (ja) 2012-11-15
CA2764454C (en) 2018-06-12
EP2438086A1 (en) 2012-04-11
GEP20135967B (en) 2013-11-11
TN2011000558A1 (en) 2013-05-24
KR20120028892A (ko) 2012-03-23
AU2010256066B2 (en) 2015-11-26
US20110003733A1 (en) 2011-01-06
ME01279B (me) 2013-06-20
JP5666569B2 (ja) 2015-02-12
US8399406B2 (en) 2013-03-19
LT2438086T (lt) 2017-04-10
EP2438086B1 (en) 2017-01-11
IL216718A0 (en) 2012-02-29
HUE034053T2 (en) 2018-01-29
SI2438086T1 (sl) 2017-05-31
TW201102083A (en) 2011-01-16
HRP20170445T1 (hr) 2017-05-19
MA33374B1 (fr) 2012-06-01
PT2438086T (pt) 2017-04-18
PL2438086T3 (pl) 2017-07-31
CN102459327B (zh) 2015-06-03
UA103526C2 (ru) 2013-10-25
NZ596848A (en) 2013-06-28
IL216718A (en) 2016-08-31
BRPI1010120A2 (pt) 2019-03-26
KR101668137B1 (ko) 2016-10-20
DK2438086T3 (en) 2017-04-10
ES2621974T3 (es) 2017-07-05
PE20120541A1 (es) 2012-05-12
EA021163B1 (ru) 2015-04-30
CO6470858A2 (es) 2012-06-29
CA2764454A1 (en) 2010-12-09
MY159464A (en) 2017-01-13
CN102459327A (zh) 2012-05-16
BRPI1010120B1 (pt) 2022-12-06
AU2010256066A1 (en) 2012-01-12
TWI457132B (zh) 2014-10-21
EA201190292A1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
CO6470858A2 (es) Composición tensioactiva reconstituida mejorada que contiene análogos de la proteína tensioactiva b (sp-b) y de la proteína tensioactiva c (sp-c)
AR093569A1 (es) Tensioactivos pulmonares reconstituidos
GT201400111A (es) Triazolopiridinas sustituidas
AR083162A1 (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2012001298A1 (es) Compuestos derivados del acido carbomoil-metilamino acetico sustituido, inhibidores de nep; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de hipertension arterial, hipertension pulmonar, insuficiencia cardiaca, entre otras.
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
MX348064B (es) Imidazopiridazinas sustituidas con amino.
MX2012008717A (es) Composiciones para el cuidado oral.
MX380453B (es) Metodo para mejorar el valor nutricional de pienso para animales.
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
NI201500118A (es) Imidazopiridazinas sustituidas
AR083126A1 (es) Composicion vacunal para el control de las infestaciones por ectoparasitos
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
PE20150908A1 (es) Fortificador de la formula
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
NI201900063A (es) Amidas aromáticas de ácido carboxílico
CL2011001777A1 (es) Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares.
MX386107B (es) Composiciones para el cuidado bucal.
AR086207A1 (es) Composiciones y metodos
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.